<DOC>
	<DOCNO>NCT00193167</DOCNO>
	<brief_summary>This non-randomized phase II study design assess response rate toxicity weekly topotecan second-line treatment patient relapse refractory metastatic colorectal cancer .</brief_summary>
	<brief_title>Weekly Topotecan Patients Treated Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Topotecan</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic colorectal cancer One previous chemotherapy metastatic disease Measurable evaluable disease Able perform activity daily live assistance Adequate bone marrow , liver , kidney function All patient must give write informed consent prior study entry . You participate study follow apply : Brain meningeal involvement Serious active infection underlie medical condition Other active neoplasm ineligible Pregnant lactate Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>